iA Global Asset Management Inc. lifted its stake in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) by 49.7% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 13,398 shares of the medical equipment provider's stock after buying an additional 4,448 shares during the quarter. iA Global Asset Management Inc.'s holdings in Hologic were worth $966,000 at the end of the most recent reporting period.
Several other large investors have also modified their holdings of the stock. First Horizon Advisors Inc. lifted its position in Hologic by 38.3% in the third quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider's stock valued at $39,000 after acquiring an additional 134 shares during the last quarter. Brooklyn Investment Group increased its position in shares of Hologic by 14.7% during the fourth quarter. Brooklyn Investment Group now owns 1,131 shares of the medical equipment provider's stock worth $82,000 after purchasing an additional 145 shares in the last quarter. Smartleaf Asset Management LLC lifted its holdings in shares of Hologic by 36.9% in the 4th quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider's stock valued at $43,000 after purchasing an additional 159 shares during the last quarter. Trivant Custom Portfolio Group LLC boosted its position in shares of Hologic by 2.1% in the 4th quarter. Trivant Custom Portfolio Group LLC now owns 8,348 shares of the medical equipment provider's stock valued at $602,000 after purchasing an additional 169 shares during the period. Finally, Loomis Sayles & Co. L P grew its stake in Hologic by 29.3% during the 3rd quarter. Loomis Sayles & Co. L P now owns 808 shares of the medical equipment provider's stock worth $66,000 after buying an additional 183 shares during the last quarter. Institutional investors and hedge funds own 94.73% of the company's stock.
Analyst Ratings Changes
Several research firms have recently weighed in on HOLX. Leerink Partnrs downgraded Hologic from a "strong-buy" rating to a "hold" rating in a report on Thursday, February 6th. Royal Bank of Canada decreased their price target on shares of Hologic from $88.00 to $85.00 and set a "sector perform" rating for the company in a research note on Thursday, February 6th. Jefferies Financial Group assumed coverage on shares of Hologic in a research note on Tuesday, December 10th. They issued a "hold" rating and a $85.00 price objective on the stock. BNP Paribas upgraded shares of Hologic to a "strong-buy" rating in a research note on Tuesday, December 10th. Finally, Morgan Stanley lowered their price target on Hologic from $84.00 to $82.00 and set an "equal weight" rating on the stock in a report on Monday, January 13th. Eleven equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus target price of $84.62.
View Our Latest Research Report on Hologic
Hologic Price Performance
Hologic stock traded down $1.09 during midday trading on Tuesday, reaching $60.80. The company's stock had a trading volume of 2,378,048 shares, compared to its average volume of 1,757,771. The firm has a market capitalization of $13.64 billion, a PE ratio of 19.18, a P/E/G ratio of 2.14 and a beta of 0.97. Hologic, Inc. has a fifty-two week low of $60.34 and a fifty-two week high of $84.67. The stock's 50 day simple moving average is $65.70 and its 200 day simple moving average is $73.66. The company has a debt-to-equity ratio of 0.52, a quick ratio of 2.78 and a current ratio of 3.49.
Hologic (NASDAQ:HOLX - Get Free Report) last announced its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $1.03 EPS for the quarter, beating the consensus estimate of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%. On average, equities research analysts forecast that Hologic, Inc. will post 4.28 earnings per share for the current year.
Hologic Profile
(
Free Report)
Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.
Featured Stories
Before you consider Hologic, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Hologic wasn't on the list.
While Hologic currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
